









Markets
/
Stocks
/
nasdaq-ctso
/

Cytosorbents Corp

CTSO

0.672USD

+0.042+6.62%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

42.20MMarket Cap

LossP/E TTM



Cytosorbents Corp

0.672

+0.042+6.62%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cytosorbents Corp

Currency: USD Updated: 2026-02-06

Key Insights

Cytosorbents Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.25.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cytosorbents Corp's Score

Industry at a Glance

Industry Ranking

119 / 205

Overall Ranking

312 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cytosorbents Corp Highlights

StrengthsRisks

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

Growing

The company is in a growing phase, with the latest annual income totaling USD 35.59M.

Fairly Valued

The company’s latest PE is -3.69, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 134.81K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.81.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.250

Target Price

+732.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cytosorbents Corp is 6.60, ranking 144 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 9.48M, representing a year-over-year increase of 1.01%, while its net profit experienced a year-over-year increase of 35.81%.

Score

Industry at a Glance

Previous score

6.60

Change



Financials

5.59

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.41

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cytosorbents Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cytosorbents Corp is 7.25, ranking 105 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -3.69, which is -68.20% below the recent high of -1.17 and -92.38% above the recent low of -7.10.

Score

Industry at a Glance

Previous score

7.25

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cytosorbents Corp is 7.00, ranking 146 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 4.00, with a high of 11.00 and a low of 0.75.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.250

Target Price

+732.94%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cytosorbents Corp

CTSO

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cytosorbents Corp is 5.56, ranking 175 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.73 and the support level at 0.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.05

Change

0.51

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.002

Sell

RSI(14)

49.286

Neutral

STOCH(KDJ)(9,3,3)

31.670

Neutral

ATR(14)

0.051

High Vlolatility

CCI(14)

6.982

Neutral

Williams %R

58.000

Sell

TRIX(12,20)

-0.139

Sell

StochRSI(14)

83.407

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.667

Buy

MA10

0.664

Buy

MA20

0.679

Sell

MA50

0.691

Sell

MA100

0.765

Sell

MA200

0.882

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cytosorbents Corp is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 29.02%, representing a quarter-over-quarter decrease of 0.34%. The largest institutional shareholder is The Vanguard, holding a total of 2.20M shares, representing 3.51% of shares outstanding, with 12.57% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Avenir Corporation

5.08M

+0.48%

Rokk LLC

4.02M

Satterfield (Thomas A Jr)

2.89M

The Vanguard Group, Inc.

Star Investors

2.20M

+3.74%

Skylands Capital, LLC

2.13M

-18.70%

Neuberger Berman, LLC

1.60M

+0.40%

CM Management, LLC

1.29M

+3.05%

Chan (Phillip P)

1.17M

+9.31%

Capponi (Vincent J)

1.11M

+8.76%

BlackRock Institutional Trust Company, N.A.

753.55K

+2.33%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cytosorbents Corp is 2.46, ranking 156 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.